2-Aryl(pyrrolidin-4-yl)acetic acids are potent agonists of sphingosine-1-phosphate (S1P) receptors

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 13, 2006, Pages 3564-3568

  Yan, Lin ^a   Budhu, Richard ^a   Huo, Pei ^a   Lynch, Christopher L ^a   Hale, Jeffrey J ^a   Mills, Sander G ^a   Hajdu, Richard ^a   Keohane, Carol A ^a   Rosenbach, Mark J ^a   Milligan, James A ^a   Shei, Gan Ju ^a   Chrebet, Gary ^a   Bergstrom, James ^a   Card, Deborah ^a   Mandala, Suzanne M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

(Pyrrolidin 4 yl)acetic acids; Immunosuppressants; Peripheral lymphocyte lowering; S1P agonists

Indexed keywords

2 PYRROLIDIN 4 YLACETIC ACID DERIVATIVE; ACETIC ACID DERIVATIVE; AZETIDINE 3 CARBOXYLIC ACID DERIVATIVE; AZETIDINE DERIVATIVE; HETEROCYCLIC CARBOXYLIC ACID; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG;

ALKYLATION; ALLYLATION; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CLEARANCE; DRUG POTENCY; DRUG RECEPTOR BINDING; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PHARMACOPHORE;

ACETIC ACIDS; ANIMALS; LYMPHOCYTE COUNT; LYSOPHOSPHOLIPIDS; MICE; MOLECULAR STRUCTURE; PROTEIN BINDING; PYRROLIDINES; RATS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33646824334     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.03.090     Document Type: Article

References (23)

1. Kovarik J.M., and Burtin P. Expert Opin. Emerg. Drugs 8 (2003) 47
2. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., Thornton R., Shei G.J., Card D., Keohane C., Rosenbach M., Hale J., Lynch C.L., Rupprecht K., Parson W., and Rosen H. Science 296 (2002) 346
3. Brinkmann V., Davis M.D., Heise C.E., Albert R., Cottens S., Hof R., Bruns C., Prieschl E., Baumruker T., Hiestand P., Foster C.A., Zollinger M., and Lynch K.R. J. Biol. Chem. 277 (2002) 21453
4. Hale J.J., Yan L., Neway W.E., Hajdu R., Bergstrom J.D., Milligan J.A., Shei G.-J., Chrebet G.L., Thornton R.A., Card D., Rosenbach M., Rosen H., and Mandala S. Bioorg. Med. Chem. 12 (2004) 4803
5. Albert R., Hinterding K., Brinkmann V., Guerini D., Müller-Hartwieg C., Knecht H., Simeon C., Streiff M., Wagner T., Welzenbach K., Zécri F., Zollinger M., Cooke N., and Francotte E. J. Med. Chem. 48 (2005) 5373
6. Cyster J.G. Annu. Rev. Immunol. 23 (2005) 127
7. Forrest M., Sun S.-Y., Hajdu R., Bergstrom J., Card D., Doherty G., Hale J., Keohane C., Meyers C., Milligan J., Mills S., Nomura N., Rosen H., Rosenbach M., Shei G.-J., Singer I.I., Tian M., West S., White V., Xie J., Proia R.L., and Mandala S. J. Pharmacol. Exp. Ther. 309 (2004) 758
8. Sanna M.G., Liao J., Jo E., Alfonso C., Ahn M.-Y., Peterson M.S., Webb B., Lefebvre S., Chun J., Gray N., and Rosen H. J. Biol. Chem. 279 (2004) 13839
9. Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkamnn V., Allende M.L., Proia R.L., and Cyster J.G. Nature 427 (2004) 355
10. Allende M.L., Dreier J.L., Mandala S., and Proia R.L. J. Biol. Chem. 279 (2004) 15396
11. Budde K., Schmouder R.L., Brunkhorst R., Nashan B., Lucker P.W., Mayer T., Choudhury S., Skerjanec A., Kraus G., and Neumayer H.H. J. Am. Soc. Nephrol. 13 (2002) 1073
12. Budde K., Schmouder R.L., Nashan B., Brunkhorst R., Lucker P.W., Mayer T., Brookman L., Nedelman J., Skerjanec A., Bohler T., and Neumayer H.H. Am. J. Transplant. 3 (2003) 846
13. Hale J.J., Doherty G., Toth L., Zhen L., Mills S.G., Hajdu R., Keohane C.A., Rosenbach M., Milligan J., Shei G.-J., Chrebet G., Bergstrom J., Card D., Rosen H., and Mandala S. Bioorg. Med. Chem. Lett. 14 (2004) 3495
14. Yan L., Hale J.J., Lynch C.L., Budhu R., Gentry A., Mills S.G., Hajdu R., Keohane C.A., Rosenbach M.J., Milligan J.A., Shei G.-J., Chrebet G., Bergstrom J., Card D., Rosen H., and Mandala S. Bioorg. Med. Chem. Lett. 14 (2004) 4861
15. Hale J.J., Lynch C.L., Neway W., Mills S.G., Hajdu R., Keohane C.A., Rosenbach M.J., Milligan J.A., Shei G.-J., Parent S.A., Chrebet G., Bergstrom J., Card D., Ferrer M., Hodder P., Strulovici B., Rosen H., and Mandala S. J. Med. Chem. 47 (2004) 6662
16. Li Z., Chen W., Hale J.J., Lynch C.L., Mills S.G., Hajdu R., Keohane C.A., Rosenbach M.J., Milligan J.A., Shei G.-J., Parent S.A., Chrebet G., Parent S.A., Bergstrom J., Card D., Forrest M., Quackenbush E.J., Wickman L.A., Vargas H., Evans R.M., Rosen H., and Mandala S. J. Med. Chem. 48 (2005) 6169
17. Rigo B., Fasseur D., Cherepy N., and Couturier D. Tetrahedron Lett. 30 (1989) 7057
18. The acylation reaction required using 2 equiv of LiHMDS to complete probably due to the generation of more acidic α-H of 12 than that of N-Boc 11. The addition of excess base was responsible for the racemization of the resulting ester.
19. Kubota H., and Rice K.C. Tetrahedron Lett. 39 (1998) 2907
20. Carlsen P.H.J., Katsuki T., Martin V.S., and Sharpless K.B. J. Org. Chem. 46 (1981) 3936
21. 35S-GTPγS functional assay (see Ref. 2a). Compound 2 (30 nM) was used as the agonist.
22. Hale J.J., Neway W., Mills S.G., Hajdu R., Keohane C.A., Rosenbach M., Milligan J., Shei G.-J., Chrebet G., Bergstrom J., Card D., Koo G.C., Koprak S.L., Jackson J.J., Rosen H., and Mandala S. Bioorg. Med. Chem. Lett. 14 (2004) 3351
23. Compounds 22f and 22g were prepared by chiral separation of their corresponding racemic methyl ester on Chiralcel OD 2 × 25 cm column (eluted with EtOH/heptane (v:v = 15:85) at rate of 8.0 mL/min), followed by saponification.